ArticleFrontiers in immunology2026
A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients with metastatic renal cell carcinoma (RCC) has improved with the introduction of novel combination therapies, including monoclonal antibodies such as ipilimumab (against CTLA-4) with nivolumab (against PD-1). However, these checkpoint inhibitors are associated with a broad spectrum of immune-related adverse events (irAEs). Herein, we report a case of suspected immune-related cerebral vasculitis occurring three weeks after initiation of ipilimumab plus nivolumab in a patient with metastatic not-otherwise-specified (NOS) renal cell carcinoma (RCC). Brain MRI demonstrated multifocal supratentorial cortico-subcortical lesions with diffusion restriction and focal cortical enhancement, compatible with acute to subacute ischemia. In the context of the clinical presentation, exclusion of common stroke mechanisms, and a favorable response to corticosteroids, both clinically and para-clinically with a marked decline in CRP, the findings were considered most consistent with possible immune-related cerebral vasculitis. Three months after only one application of combined immunotherapy, a restaging CT scan showed an objective response in terms of partial remission. However, the metastatic RCC progressed after another 3 months, and the patient received two lines of tyrosine kinase inhibitors (sunitinib and cabozantinib). The patient died due to cancer progression, with an overall survival of 10.5 months. This case report provides experience with the management of possible immune-related cerebral vasculitis in patients with a rare malignancy. Severe cerebral vasculitis requires hospitalization with prompt diagnostic workup and immunosuppressive treatment. Despite the preterm permanent discontinuation of immunotherapy, the patients can benefit from the systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.